Anticoagulation Forum/LinkedIn
Sep 5, 2025, 12:55
RENOVE and API-CAT Trials: Exploring Secondary VTE Prevention
Anticoagulation Forum shared on LinkedIn:
”Missed it live? The recording of our recent webinar ‘Secondary VTE Prevention: To Reduce or Not to Reduce? A Focus on RENOVE and API-CAT‘ is now available!
Watch it now on our Archived Webinars page.
Dive into one of the most debated questions in anticoagulation—when and how to reduce the dose.
Our expert panel breaks down results from the RENOVE and API-CAT trials, with practical insights you can apply in your practice right away.
What you’ll take away:
- DOAC dosing strategies for extended secondary VTE prevention
- Evidence-based guidance for individualized care
- Real-world tips from leading clinicians
Free for AC Forum members — and joining is quick and free.
Don’t miss the chance to catch up on this timely and dynamic discussion!”
Watch the webinar here.
Find the latest webinars and seminars on thrombosis featured in Hemostasis Today.
-
Aug 11, 2026, 11:47Rucha Patil: Strengthening Evidence-Based Haemophilia Care Across India
-
Aug 11, 2026, 11:38Maria Hadjidemetriou: The Patient Perspective in Thalassemia Care
-
Aug 11, 2026, 11:04Wolfgang Miesbach: The Critical Need for Tailored Dosing in VWD
-
Aug 11, 2026, 08:20Hasan Abbas Zaheer: Strengthening Universal Access to Safe Blood in Pakistan
-
Aug 11, 2026, 08:07Nicola Pozzi: Advancing Hemostasis Through Scientific Collaboration at Hemostasis GRC
-
Aug 11, 2026, 07:50When Access to Care Changes Everything – WFH
-
Aug 11, 2026, 07:41Kevin Land: How Cellular Therapy Is Changing Transfusion Medicine
-
Aug 11, 2026, 07:35Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
-
Aug 11, 2026, 07:28Archil Jaliashvili: When Every Minute Matters Time Becomes a Therapy